Optical coherence tomography findings in Parkinson's disease

Aydin, Turkoglu Sule; Doğan, Ümit; Nur, Ogun Muhammed; Ulaş, Fatih; Keleş, Asena; Nefise, Ozturk Yavas; Serpil, Yildiz

doi:10.1016/j.kjms.2017.11.006

Cited by 29 publications

(29 citation statements)

References 28 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 36 studies were all published between 2011 and 2020. The flow diagram of the search procedure is shown in Figure 1 and the characteristics of the included studies are described in Table 1 [11,19–53]. Patients with PD had a mean age of 64.8 (53.4–74.61) years and a mean duration of 6.7 (0.675–18.44) years.…”

Section: Resultsmentioning

confidence: 99%

Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta‐analysis

Zhou

Tao

2020

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose Retinal pathological changes may precede or accompany the deterioration of brain tissue in Parkinson's disease (PD). The purpose of this meta‐analysis was to assess the usefulness of optical coherence tomography (OCT) measurements as potential imaging biomarkers for PD. Methods PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched for observational studies (published prior to 30 May 2020) comparing the OCT measurements between PD patients and healthy controls (HCs). Our main end‐points were peripapillary retinal nerve fiber layer (pRNFL) thickness, macular ganglion cell complex thickness, macular thickness and macular volume. Pooled data were assessed by use of a random‐effects model. Results A total of 36 observational studies were identified that included 1712 patients with PD (2548 eyes) and 1778 HCs (2646 eyes). Compared with the HC group, the PD group showed a significant reduction in mean pRNFL thickness (weighted mean difference [WMD] −3.51 μm, 95% confidence interval [CI] −4.84, −2.18; p = 0.000), all quadrants at the pRNFL (WMD range −7.65 to −2.44 μm, all p < 0.05), macular fovea thickness (WMD −5.62 μm, 95% CI −7.37, −3.87; p = 0.000), all outer sector thicknesses at the macula (WMD range −4.68 to −4.10 μm, all p < 0.05), macular volume (WMD −0.21 mm3, 95% CI −0.36, −0.06; p < 0.05) and macular ganglion cell complex thickness (WMD −4.18 μm, 95% CI −6.07, −2.29; p < 0.05). Conclusions Our pooled data confirmed robust associations between retinal OCT measurements and PD, highlighting the usefulness of OCT measurements as potential imaging biomarkers for PD.

show abstract

Section: Resultsmentioning

confidence: 99%

Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta‐analysis

Zhou

Tao

2020

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“… 11 Similarly, another study found that toxic accumulation of iron, which is known to play a role in PD, was two-folds higher among patients with AMD compared to that of controls. 12 …”

Section: Discussionmentioning

confidence: 99%

Risk of Parkinson’s disease in patients with neovascular age-related macular degeneration

Etminan

Samii

2018

Journal of Current Ophthalmology

View full text Add to dashboard Cite

PurposeTo examine the risk of developing Parkinson's Disease (PD) in patients who are newly diagnosed with neovascular age-related macular degeneration (nAMD).MethodsThis was a cohort study using the British Columbia (BC) Retinal Disease Database. Data from 2009 to 2013 was accessed. Rates of PD in patients prior to the diagnosis of nAMD were computed and compared to the rates of patients newly diagnosed with PD after the diagnosis of nAMD.ResultsThe rate of PD prior to the diagnosis of nAMD was 1.42 per 100,000 person-years. The rate of PD after the diagnosis of nAMD was 2.88/100,000 person-years. The rate ratio was 2.03 (95% CI; 1.31–3.16).ConclusionsThe findings suggest that patients who are diagnosed with nAMD are at a significantly higher risk of developing PD later in life. More studies are needed to identify the pathological mechanism between the two diseases.

show abstract

“…Significant thinning in global, superior, inferior, nasal and temporal pRNFL have been observed. 89,91,93–97,99–104,106,119 In contrast, several studies have reported no significant differences. 77,87,88,90,92,105 A total of 13 case-control studies were included in a meta-analysis, supporting pRNFL thinning in all four quadrants (WMD = 25.76, 95% CI: 28.99–22.53, p = 0.0005).…”

Section: Parkinson’s Diseasementioning

confidence: 90%

Retinal correlates of neurological disorders

Yap

Si²,

et al. 2019

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Considering the retina as an extension of the brain provides a platform from which to study diseases of the nervous system. Taking advantage of the clear optical media of the eye and ever-increasing resolution of modern imaging techniques, retinal morphology can now be visualized at a cellular level in vivo. This has provided a multitude of possible biomarkers and investigative surrogates that may be used to identify, monitor and study diseases until now limited to the brain. In many neurodegenerative conditions, early diagnosis is often very challenging due to the lack of tests with high sensitivity and specificity, but, once made, opens the door to patients accessing the correct treatment that can potentially improve functional outcomes. Using retinal biomarkers in vivo as an additional diagnostic tool may help overcome the need for invasive tests and histological specimens, and offers the opportunity to longitudinally monitor individuals over time. This review aims to summarise retinal biomarkers associated with a range of neurological conditions including Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and prion diseases from a clinical perspective. By comparing their similarities and differences according to primary pathological processes, we hope to show how retinal correlates can aid clinical decisions, and accelerate the study of this rapidly developing area of research.

show abstract

Optical coherence tomography findings in Parkinson's disease

Cited by 29 publications

References 28 publications

Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta‐analysis

Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta‐analysis

Risk of Parkinson’s disease in patients with neovascular age-related macular degeneration

Retinal correlates of neurological disorders

Contact Info

Product

Resources

About